The stock of Sangamo Biosciences, Inc. (NASDAQ:SGMO) hit a new 52-week low and has $3.62 target or 11.00% below today’s $4.07 share price. The 9 months bearish chart indicates high risk for the $263.78 million company. The 1-year low was reported on Oct, 13 by Barchart.com. If the $3.62 price target is reached, the company will be worth $29.02 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 250,471 shares traded hands. Sangamo Biosciences, Inc. (NASDAQ:SGMO) has declined 25.99% since March 10, 2016 and is downtrending. It has underperformed by 33.51% the S&P500.
Analysts await Sangamo Biosciences, Inc. (NASDAQ:SGMO) to report earnings on October, 26. They expect $-0.25 EPS, down 92.31% or $0.12 from last year’s $-0.13 per share. After $-0.38 actual EPS reported by Sangamo Biosciences, Inc. for the previous quarter, Wall Street now forecasts -34.21% EPS growth.
Sangamo Biosciences, Inc. (NASDAQ:SGMO) Ratings Coverage
Out of 7 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 5 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 71% are positive. Sangamo Biosciences has been the topic of 9 analyst reports since August 8, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Friday, October 23 by Jefferies. The stock has “Buy” rating given by Jefferies on Wednesday, September 2. The firm has “Buy” rating by JP Morgan given on Thursday, September 3. JP Morgan maintained Sangamo Biosciences, Inc. (NASDAQ:SGMO) rating on Saturday, August 8. JP Morgan has “Overweight” rating and $22 price target. The stock of Sangamo Biosciences, Inc. (NASDAQ:SGMO) has “Outperform” rating given on Friday, December 4 by Wells Fargo. The rating was maintained by Cowen & Co with “Buy” on Friday, September 4. The company was downgraded on Thursday, August 4 by Janney Capital. Zacks downgraded Sangamo Biosciences, Inc. (NASDAQ:SGMO) on Tuesday, September 8 to “Sell” rating. The firm earned “Buy” rating on Wednesday, September 2 by Wedbush.
According to Zacks Investment Research, “Sangamo BioSciences, Inc. is a leader in the development of novel transcription factors for the regulation of gene expression. Transcription factors are proteins that turn genes on or off by recognizing specific DNA sequences. The Universal Gene Recognition technology platform enables the engineering of a class of transcription factors known as zinc finger DNA binding proteins.”
Insitutional Activity: The institutional sentiment decreased to 0.81 in 2016 Q2. Its down 0.57, from 1.38 in 2016Q1. The ratio dived, as 20 funds sold all Sangamo Biosciences, Inc. shares owned while 42 reduced positions. 13 funds bought stakes while 37 increased positions. They now own 45.72 million shares or 4.72% less from 47.99 million shares in 2016Q1.
Price T Rowe Associates Md holds 98,500 shares or 0% of its portfolio. Washington Trust Fincl Bank has 0% invested in the company for 3,000 shares. Us Comml Bank De last reported 0% of its portfolio in the stock. Northern Trust reported 879,456 shares or 0% of all its holdings. New York State Common Retirement Fund holds 0% or 89,850 shares in its portfolio. Ascend Lc last reported 0.16% of its portfolio in the stock. Citigroup last reported 10,913 shares in the company. Wexford Cap Ltd Partnership holds 0.05% or 49,432 shares in its portfolio. Adage Cap Prtnrs Group Incorporated Ltd Llc accumulated 0.04% or 2.50 million shares. Brick & Kyle Assoc accumulated 0% or 1,100 shares. Cormorant Asset Ltd Liability has invested 1.15% of its portfolio in Sangamo Biosciences, Inc. (NASDAQ:SGMO). Awm Invest accumulated 92,200 shares or 0.11% of the stock. Ladenburg Thalmann Fincl accumulated 0% or 4,500 shares. Pdt Prns Limited Liability Company last reported 0.06% of its portfolio in the stock. Moreover, Grp Incorporated One Trading Lp has 0.01% invested in Sangamo Biosciences, Inc. (NASDAQ:SGMO) for 144,935 shares.
More recent Sangamo Biosciences, Inc. (NASDAQ:SGMO) news were published by: Fool.com which released: “Why Sangamo Biosciences, Inc. Fell 29% Today” on August 04, 2016. Also Prnewswire.com published the news titled: “Sangamo BioSciences Announces Retirement Of Edward Lanphier As President And …” on June 01, 2016. Prnewswire.com‘s news article titled: “Sangamo BioSciences Announces Second Quarter 2016 Conference Call and Webcast” with publication date: July 27, 2016 was also an interesting one.
SGMO Company Profile
Sangamo Biosciences Inc., incorporated on June 22, 1995, is a clinical-stage biopharmaceutical company. The Firm is focused on the research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. The Firm is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics, which are therapeutic products for the treatment of genetic disease. The Company’s ZFP Therapeutic, SB-728, a ZFP nuclease (ZFN)-modified autologous cell product for the treatment of Human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS), is the therapeutic application of its ZFN genome editing technology and is being evaluated in an ongoing Phase II study of ZFN-modified T-cells (SB-728-T-1101, Cohort 3) and a Phase I/II study of modified hematopoietic stem cells (SB-728mR-HSPC) in HIV-infected subjects. The Firm has preclinical programs in hemophilia A and other Lysergic acid diethylamide (LSDs), and research stage programs in other monogenic diseases, including certain central nervous system (CNS) disorders and cancer immunotherapy.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.